Table 2

Prescribers’ responses rating their concern of potential consequences when switching a patient’s treatment from a reference biologic to a biosimilar or vice versa

Potential consequence (weighted average)AllEuropeAsia-Pacific
Potential loss of clinical efficacy3.293.233.30
Potential for adverse events3.353.323.35
Potential for increased risk of immune reactions3.353.393.17
  • Weighted average of prescribers’ responses, by region, on a scale of 1 (not at all) to 5 (very).